retatrutide weight loss phase 2 trial results New 3 obesity trials came out and the are impressive: - 1,152 patients with obesity & type diabetes retatrutide weight loss phase 2

Researchers from University of Oxford, University of Dundee, University of Copenhagen, University of British Columbia, Churchill Hospital, Newcastle University, University of Bath and University of Exeter also contributed to the work

As part of its earnings report, the company outlined several initiatives within its end-to-end transformation, among them are: Optimizing SKUs and reducing complexity

Participants without diabetes averaged 22.4% weight loss at 48 weeks (8mg dose), while those with type 2 diabetes averaged 19.7%

Reduction is gated on stored fat: the participants in that substudy all started with at least 10% liver fat, and the size of the drop tracked how much was there at baseline